dc.contributor.author | Brumpton, Ben Michael | |
dc.contributor.author | Fritsche, Lars | |
dc.contributor.author | Zheng, Jie | |
dc.contributor.author | Nielsen, Jonas Bille | |
dc.contributor.author | Mannila, Maria Nastase | |
dc.contributor.author | Surakka, Ida | |
dc.contributor.author | Rasheed, Humaira | |
dc.contributor.author | Vie, Gunnhild Åberge | |
dc.contributor.author | Graham, Sarah E. | |
dc.contributor.author | Gabrielsen, Maiken Elvestad | |
dc.contributor.author | Laugsand, Lars Erik | |
dc.contributor.author | Aukrust, Pål | |
dc.contributor.author | Vatten, Lars Johan | |
dc.contributor.author | Damås, Jan Kristian | |
dc.contributor.author | Ueland, Thor | |
dc.contributor.author | Janszky, Imre | |
dc.contributor.author | Zwart, John-Anker | |
dc.contributor.author | van't Hooft, Ferdinand M. | |
dc.contributor.author | Seidah, Nabil Georges | |
dc.contributor.author | Hveem, Kristian | |
dc.contributor.author | Willer, Cristen | |
dc.contributor.author | Smith, George Davey | |
dc.contributor.author | Åsvold, Bjørn Olav | |
dc.date.accessioned | 2020-03-23T08:39:40Z | |
dc.date.available | 2020-03-23T08:39:40Z | |
dc.date.created | 2019-04-27T13:21:40Z | |
dc.date.issued | 2019 | |
dc.identifier.issn | 2574-8300 | |
dc.identifier.uri | https://hdl.handle.net/11250/2648012 | |
dc.description.abstract | PCSK9 (proprotein convertase subtilisin/kexin type 9) inhibitors reduce serum LDL (low-density lipoprotein) cholesterol (LDL-C) by increasing uptake in the liver. Although some long-term trials have evaluated their safety, broad investigations of outcomes over the lifetime, leveraging genetic variation in serum PCSK9, have seldomly been conducted. We investigated effects of these variants on a range of outcomes to explore unanticipated effects of long-term PCSK9 inhibition. | en_US |
dc.language.iso | eng | en_US |
dc.publisher | American Heart Association | en_US |
dc.title | Variation in serum PCSK9 (proprotein convertase subtilisin/kexin type 9), cardiovascular disease risk, and an investigation of potential unanticipated effects of PCSK9 inhibition | en_US |
dc.type | Peer reviewed | en_US |
dc.type | Journal article | en_US |
dc.description.version | acceptedVersion | en_US |
dc.source.volume | 12 | en_US |
dc.source.journal | Circulation. Genomic and precision medicine | en_US |
dc.source.issue | 1 | en_US |
dc.identifier.doi | 10.1161/CIRCGEN.118.002335 | |
dc.identifier.cristin | 1694350 | |
dc.relation.project | Norges forskningsråd: 248817 | en_US |
dc.relation.project | Norges forskningsråd: 299113 | en_US |
dc.relation.project | Stiftelsen Kristian Gerhard Jebsen: SKGJ-MED-015 | en_US |
dc.relation.project | Norges forskningsråd: 250335 | en_US |
dc.description.localcode | © 2019. This is the authors' accepted and refereed manuscript to the article. The final authenticated version is available online at: http://dx.doi.org/10.1161/CIRCGEN.118.002335 | en_US |
cristin.ispublished | true | |
cristin.fulltext | original | |
cristin.fulltext | postprint | |
cristin.qualitycode | 1 | |